All In Biotech

Drug Trial Radar · NCT03004417

Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

A Randomised, Double-blind,Placebo Controlled, Repeated Dose, Three-way Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

Last checked: Nov 19, 2026Latest source record: Jul 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Oct 31, 2016

Primary completion

Dec 28, 2017

Study completion Dec 28, 2017

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
Collaborators
SGS S.A.
First posted
Dec 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Effect of CHF 6001 on biomarkers of inflammation in induced sputum and in blood, on pulmonary function and on symptoms benefits in comparison with placebo.

Conditions

  • COPD

Interventions

  • CHF 6001 Dose1Drug

    CHF 6001 plus placebo

  • CHF 6001 Dose2Drug

    CHF 6001 only (high dose)

  • PlaceboOther

    Placebo only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sputum biomarkersTime frame: Change from baseline to end of treatment (mean Day 20, 26 and 32 values) at each period;
  2. Sputum biomarkersTime frame: Predose and end of treatment at Day 32 of each period
  3. Sputum cell countTime frame: Change from baseline to end of treatment (mean Day 20, 26 and 32 values) at each period;
  4. Blood BiomarkersTime frame: Change from baseline to Day 32 of each period;
  5. Blood BiomarkersTime frame: Predose and end of treatment at Day 32 of each period
  6. Lung function: SpirometryTime frame: Change from baseline to Day 20 Day 26 and 32 of each period
  7. Lung function: OscillometryTime frame: Change from baseline to Day 32 of each period
  8. PK: AUC0-12h,ssTime frame: on Day 32 (steady state) of each period.
  9. PK: CmaxTime frame: on Day 32 (steady state) of each period.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medicines Evaluation Unit Ltd

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.